{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T14:29:08Z","timestamp":1760711348055,"version":"3.37.3"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T00:00:00Z","timestamp":1712880000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T00:00:00Z","timestamp":1712880000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s00467-024-06367-9","type":"journal-article","created":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T08:01:55Z","timestamp":1712908915000},"page":"3193-3200","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Do we really need cyclophosphamide for lupus nephritis?"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8991-8277","authenticated-orcid":false,"given":"Scott E.","family":"Wenderfer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer C.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,4,12]]},"reference":[{"key":"6367_CR1","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1038\/pr.2016.247","volume":"81","author":"SE Wenderfer","year":"2017","unstructured":"Wenderfer SE, Ruth NM, Brunner HI (2017) Advances in the care of children with lupus nephritis. Pediatr Res 81:406\u2013414. https:\/\/doi.org\/10.1038\/pr.2016.247","journal-title":"Pediatr Res"},{"key":"6367_CR2","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.1002\/art.34472","volume":"64","author":"LT Hiraki","year":"2012","unstructured":"Hiraki LT, Feldman CH, Liu J et al (2012) Prevalence, incidence, and demographics of systemic lupus erythematosus and lupus nephritis from 2000 to 2004 among children in the US medicaid beneficiary population. Arthritis Rheumatol 64:2669\u20132676. https:\/\/doi.org\/10.1002\/art.34472","journal-title":"Arthritis Rheumatol"},{"key":"6367_CR3","doi-asserted-by":"publisher","first-page":"65","DOI":"10.2215\/CJN.07810621","volume":"17","author":"SE Wenderfer","year":"2022","unstructured":"Wenderfer SE, Chang JC, Goodwin Davies A et al (2022) Using a multi-institutional pediatric learning health system to identify systemic lupus erythematosus and lupus nephritis: development and validation of computable phenotypes. Clin J Am Soc Nephrol 17:65\u201374. https:\/\/doi.org\/10.2215\/CJN.07810621","journal-title":"Clin J Am Soc Nephrol"},{"key":"6367_CR4","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.3899\/jrheum.180310","volume":"45","author":"C Garnier","year":"2018","unstructured":"Garnier C, Ribes D, Chauveau D et al (2018) Zoster after cyclophosphamide for systemic lupus erythematosus or vasculitis: incidence, risk factors, and effect of antiviral prophylaxis. J Rheumatol 45:1541\u20131548. https:\/\/doi.org\/10.3899\/jrheum.180310","journal-title":"J Rheumatol"},{"key":"6367_CR5","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1093\/rheumatology\/kead447","volume":"63","author":"EY Chan","year":"2023","unstructured":"Chan EY, Yap DY, Wong WH et al (2023) Renal relapse in children and adolescents with childhood-onset lupus nephritis: a 20-year study. Rheumatology. https:\/\/doi.org\/10.1093\/rheumatology\/kead447","journal-title":"Rheumatology"},{"key":"6367_CR6","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1007\/s00467-015-3202-7","volume":"31","author":"C Quinlan","year":"2016","unstructured":"Quinlan C, Marks SD, Tullus K (2016) Why are kids with lupus at an increased risk of cardiovascular disease? Pediatr Nephrol 31:861\u2013883. https:\/\/doi.org\/10.1007\/s00467-015-3202-7","journal-title":"Pediatr Nephrol"},{"key":"6367_CR7","doi-asserted-by":"publisher","first-page":"46","DOI":"10.2215\/CJN.03280807","volume":"3","author":"YE Chen","year":"2008","unstructured":"Chen YE, Korbet SM, Katz RS et al (2008) Value of a complete or partial remission in severe lupus nephritis. Clin J Am Soc Nephrol 3:46\u201353","journal-title":"Clin J Am Soc Nephrol"},{"key":"6367_CR8","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1093\/rheumatology\/keab746","volume":"61","author":"C De Mutiis","year":"2021","unstructured":"De Mutiis C, Wenderfer SE, Orjuela A et al (2021) Defining renal remission in an international cohort of 248 children and adolescents with lupus nephritis. Rheumatology 61:2563\u20132571. https:\/\/doi.org\/10.1093\/rheumatology\/keab746","journal-title":"Rheumatology"},{"key":"6367_CR9","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1007\/s00467-007-0447-9","volume":"22","author":"D Askenazi","year":"2007","unstructured":"Askenazi D, Myones B, Kamdar A et al (2007) Outcomes of children with proliferative lupus nephritis: the role of protocol renal biopsy. Pediatr Nephrol 22:981\u2013986. https:\/\/doi.org\/10.1007\/s00467-007-0447-9","journal-title":"Pediatr Nephrol"},{"key":"6367_CR10","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1002\/art.30350","volume":"63","author":"LT Hiraki","year":"2011","unstructured":"Hiraki LT, Lu B, Alexander SR et al (2011) End-stage renal disease due to lupus nephritis among children in the US, 1995\u20132006. Arthritis Rheumatol 63:1988\u20131997. https:\/\/doi.org\/10.1002\/art.30350","journal-title":"Arthritis Rheumatol"},{"key":"6367_CR11","first-page":"2635","volume":"29","author":"S Hagelberg","year":"2002","unstructured":"Hagelberg S, Lee Y, Bargman J et al (2002) Longterm followup of childhood lupus nephritis. J Rheumatol 29:2635\u20132642","journal-title":"J Rheumatol"},{"key":"6367_CR12","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1002\/art.38220","volume":"66","author":"BI Freedman","year":"2014","unstructured":"Freedman BI, Langefeld CD, Andringa KK et al (2014) End-stage kidney disease in African Americans with lupus nephritis associates with APOL1. Arthritis Rheumatol 66:390\u2013396. https:\/\/doi.org\/10.1002\/art.38220","journal-title":"Arthritis Rheumatol"},{"key":"6367_CR13","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.3390\/jcm12041424","volume":"12","author":"G Petrovic","year":"2023","unstructured":"Petrovic G, Pasic S, Soldatovic I (2023) Association of antiphospholipid antibodies with clinical manifestations in children with systemic lupus erythematosus. J Clin Med 12:1424. https:\/\/doi.org\/10.3390\/jcm12041424","journal-title":"J Clin Med"},{"key":"6367_CR14","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s00467-004-1419-y","volume":"19","author":"M Zappitelli","year":"2004","unstructured":"Zappitelli M, Duffy C, Bernard C et al (2004) Clinicopathological study of the WHO classification in childhood lupus nephritis. Pediatr Nephrol 19:503\u2013510. https:\/\/doi.org\/10.1007\/s00467-004-1419-y","journal-title":"Pediatr Nephrol"},{"key":"6367_CR15","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s00467-006-0296-y","volume":"22","author":"SD Marks","year":"2007","unstructured":"Marks SD, Sebire NJ, Pilkington C et al (2007) Clinicopathological correlations of paediatric lupus nephritis. Pediatr Nephrol 22:77\u201383. https:\/\/doi.org\/10.1007\/s00467-006-0296-y","journal-title":"Pediatr Nephrol"},{"key":"6367_CR16","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s00467-007-0619-7","volume":"23","author":"M Zappitelli","year":"2008","unstructured":"Zappitelli M, Duffy CM, Bernard C et al (2008) Evaluation of activity, chronicity and tubulointerstitial indices for childhood lupus nephritis. Pediatr Nephrol 23:83\u201391. https:\/\/doi.org\/10.1007\/s00467-007-0619-7","journal-title":"Pediatr Nephrol"},{"key":"6367_CR17","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1007\/s00467-006-0286-0","volume":"22","author":"BS Lee","year":"2007","unstructured":"Lee BS, Cho HY, Kim EJ et al (2007) Clinical outcomes of childhood lupus nephritis: a single center\u2019s experience. Pediatr Nephrol 22:222\u2013231. https:\/\/doi.org\/10.1007\/s00467-006-0286-0","journal-title":"Pediatr Nephrol"},{"key":"6367_CR18","first-page":"1233","volume-title":"Goodman and Gilman\u2019s the pharmacological basis of therapeutics","author":"B Chabner","year":"1996","unstructured":"Chabner B, Allegra C, Curt G et al (1996) Antineoplastic agents. In: Hardman J, Limbird L, Molinoff P, Ruddon R, Gilman A (eds) Goodman and Gilman\u2019s the pharmacological basis of therapeutics. McGraw-Hill, New York, pp 1233\u20131287"},{"key":"6367_CR19","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1056\/NEJM198603063141004","volume":"314","author":"HA Austin 3rd","year":"1986","unstructured":"Austin HA 3rd, Klippel JH, Balow JE et al (1986) Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 314:614\u2013619. https:\/\/doi.org\/10.1056\/NEJM198603063141004","journal-title":"N Engl J Med"},{"key":"6367_CR20","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa043731","volume":"353","author":"EM Ginzler","year":"2005","unstructured":"Ginzler EM, Dooley MA, Aranow C et al (2005) Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 353:2219\u20132228","journal-title":"N Engl J Med"},{"key":"6367_CR21","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1681\/ASN.2008101028","volume":"20","author":"GB Appel","year":"2009","unstructured":"Appel GB, Contreras G, Dooley MA et al (2009) Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 20:1103\u20131112. https:\/\/doi.org\/10.1681\/ASN.2008101028","journal-title":"J Am Soc Nephrol"},{"key":"6367_CR22","doi-asserted-by":"publisher","first-page":"CD002922","DOI":"10.1002\/14651858.CD002922.pub4","volume":"6","author":"DJ Tunnicliffe","year":"2018","unstructured":"Tunnicliffe DJ, Palmer SC, Henderson L et al (2018) Immunosuppressive treatment for proliferative lupus nephritis. Cochrane Database Syst Rev 6:CD002922. https:\/\/doi.org\/10.1002\/14651858.CD002922.pub4","journal-title":"Cochrane Database Syst Rev"},{"key":"6367_CR23","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1007\/s00296-010-1389-2","volume":"31","author":"CA Silva","year":"2011","unstructured":"Silva CA, Deen ME, Febronio MV et al (2011) Hormone profile in juvenile systemic lupus erythematosus with previous or current amenorrhea. Rheumatol Int 31:1037\u20131043. https:\/\/doi.org\/10.1007\/s00296-010-1389-2","journal-title":"Rheumatol Int"},{"key":"6367_CR24","doi-asserted-by":"publisher","first-page":"ii62","DOI":"10.1136\/annrheumdis-2012-202195","volume":"72","author":"CGM Kallenberg","year":"2012","unstructured":"Kallenberg CGM (2012) Could we abandon cyclophosphamide in systemic vasculitis and lupus nephritis? Ann Rheum Dis 72:ii62\u2013ii65. https:\/\/doi.org\/10.1136\/annrheumdis-2012-202195","journal-title":"Ann Rheum Dis"},{"key":"6367_CR25","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1007\/s00467-014-2897-1","volume":"30","author":"R Gajjar","year":"2015","unstructured":"Gajjar R, Miller SD, Meyers KE et al (2015) Fertility preservation in patients receiving cyclophosphamide therapy for renal disease. Pediatr Nephrol 30:1099\u20131106. https:\/\/doi.org\/10.1007\/s00467-014-2897-1","journal-title":"Pediatr Nephrol"},{"key":"6367_CR26","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1002\/art.40079","volume":"69","author":"F Tamirou","year":"2017","unstructured":"Tamirou F, Husson SN, Gruson D et al (2017) Brief report: the Euro-lupus low-dose intravenous cyclophosphamide regimen does not impact the ovarian reserve, as measured by serum levels of anti-Mullerian hormone. Arthritis Rheumatol 69:1267\u20131271. https:\/\/doi.org\/10.1002\/art.40079","journal-title":"Arthritis Rheumatol"},{"key":"6367_CR27","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1002\/art.39024","volume":"67","author":"HI Brunner","year":"2015","unstructured":"Brunner HI, Silva CA, Reiff A et al (2015) Randomized double-blinded dose escalation trial of triptorelin for ovary protection in childhood-onset systemic lupus erythematosus. Arthritis Rheumatol 67:1377\u20131385. https:\/\/doi.org\/10.1002\/art.39024","journal-title":"Arthritis Rheumatol"},{"key":"6367_CR28","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1046\/j.1523-1755.2002.00279.x","volume":"61","author":"M Haubitz","year":"2002","unstructured":"Haubitz M, Bohnenstengel F, Brunkhorst R et al (2002) Cyclophosphamide pharmacokinetics and dose requirements in patients with renal insufficiency. Kidney Int 61:1495\u20131501. https:\/\/doi.org\/10.1046\/j.1523-1755.2002.00279.x","journal-title":"Kidney Int"},{"key":"6367_CR29","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s40272-023-00609-3","volume":"26","author":"EY Chan","year":"2024","unstructured":"Chan EY, Lai FF, Ma AL et al (2024) Managing lupus nephritis in children and adolescents. Paediatr Drugs 26:145\u2013161. https:\/\/doi.org\/10.1007\/s40272-023-00609-3","journal-title":"Paediatr Drugs"},{"key":"6367_CR30","doi-asserted-by":"publisher","first-page":"bcr2017221735","DOI":"10.1136\/bcr-2017-221735","volume":"2018","author":"G Eden","year":"2018","unstructured":"Eden G, Kuhn-Velten WN, Hafer C et al (2018) Enhanced elimination of cyclophosphamide by high cut-off haemodialysis: single-dose pharmacokinetics in a patient with cast nephropathy. BMJ Case Rep 2018:bcr2017221735. https:\/\/doi.org\/10.1136\/bcr-2017-221735","journal-title":"BMJ Case Rep"},{"key":"6367_CR31","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1093\/rheumatology\/41.7.780","volume":"41","author":"GE Katsifis","year":"2002","unstructured":"Katsifis GE, Tzioufas AG, Vlachoyiannopoulos PG et al (2002) Risk of myelotoxicity with intravenous cyclophosphamide in patients with systemic lupus erythematosus. Rheumatology 41:780\u2013786. https:\/\/doi.org\/10.1093\/rheumatology\/41.7.780","journal-title":"Rheumatology"},{"key":"6367_CR32","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1177\/096120339100100106","volume":"1","author":"FA Houssiau","year":"1991","unstructured":"Houssiau FA, D\u2019Cruz DP, Haga HJ et al (1991) Short course of weekly low-dose intravenous pulse cyclophosphamide in the treatment of lupus nephritis: a preliminary study. Lupus 1:31\u201335","journal-title":"Lupus"},{"key":"6367_CR33","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1136\/ard.2008.102533","volume":"69","author":"FA Houssiau","year":"2010","unstructured":"Houssiau FA, Vasconcelos C, D\u2019Cruz D et al (2010) The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis 69:61\u201364. https:\/\/doi.org\/10.1136\/ard.2008.102533","journal-title":"Ann Rheum Dis"},{"key":"6367_CR34","doi-asserted-by":"publisher","first-page":"3096","DOI":"10.1002\/art.38790","volume":"66","author":"The Access Trial Group","year":"2014","unstructured":"Access Trial Group (2014) Treatment of lupus nephritis with abatacept: the abatacept and cyclophosphamide combination efficacy and safety study. Arthritis Rheumatol 66:3096\u20133104. https:\/\/doi.org\/10.1002\/art.38790","journal-title":"Arthritis Rheumatol"},{"key":"6367_CR35","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1002\/art.39067","volume":"67","author":"D Wofsy","year":"2015","unstructured":"Wofsy D, Diamond B, Houssiau FA (2015) Crossing the Atlantic\u2014the Euro-Lupus nephritis regimen in North America. Arthritis Rheumatol 67:1144\u20131146. https:\/\/doi.org\/10.1002\/art.39067","journal-title":"Arthritis Rheumatol"},{"key":"6367_CR36","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.kint.2021.05.015","volume":"100","author":"BH Rovin","year":"2021","unstructured":"Rovin BH, Adler SG, Barratt J et al (2021) Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. Kidney Int 100:753\u2013779. https:\/\/doi.org\/10.1016\/j.kint.2021.05.015","journal-title":"Kidney Int"},{"key":"6367_CR37","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1136\/ard-2023-224762","volume":"83","author":"A Fanouriakis","year":"2023","unstructured":"Fanouriakis A, Kostopoulou M, Andersen J et al (2023) EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis 83:15\u201329. https:\/\/doi.org\/10.1136\/ard-2023-224762","journal-title":"Ann Rheum Dis"},{"key":"6367_CR38","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1007\/s00467-005-1983-9","volume":"20","author":"S Fujinaga","year":"2005","unstructured":"Fujinaga S, Kaneko K, Ohtomo Y et al (2005) Induction therapy with low-dose intravenous cyclophosphamide, oral mizoribine, and steroids for severe lupus nephritis in children. Pediatr Nephrol 20:1500\u20131503. https:\/\/doi.org\/10.1007\/s00467-005-1983-9","journal-title":"Pediatr Nephrol"},{"key":"6367_CR39","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s00467-009-1291-x","volume":"25","author":"E Baskin","year":"2010","unstructured":"Baskin E, Ozen S, Cakar N et al (2010) The use of low-dose cyclophosphamide followed by AZA\/MMF treatment in childhood lupus nephritis. Pediatr Nephrol 25:111\u2013117. https:\/\/doi.org\/10.1007\/s00467-009-1291-x","journal-title":"Pediatr Nephrol"},{"key":"6367_CR40","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1002\/art.42725","volume":"76","author":"CS Wang","year":"2023","unstructured":"Wang CS, Sadun RE, Zhou W et al (2023) Renal response outcomes of the EuroLupus and NIH cyclophosphamide dosing regimens in childhood-onset proliferative lupus nephritis. Arthritis Rheumatol 76:469\u2013478. https:\/\/doi.org\/10.1002\/art.42725","journal-title":"Arthritis Rheumatol"},{"key":"6367_CR41","doi-asserted-by":"publisher","first-page":"607","DOI":"10.3899\/jrheum.210428","volume":"49","author":"L Cannon","year":"2022","unstructured":"Cannon L, Wenderfer SE, Lewandowski LB et al (2022) Use of EuroLupus cyclophosphamide dosing for the treatment of lupus nephritis in childhood-onset systemic lupus erythematosus in North America. J Rheumatol 49:607\u2013614. https:\/\/doi.org\/10.3899\/jrheum.210428","journal-title":"J Rheumatol"},{"key":"6367_CR42","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1056\/NEJM200010193431604","volume":"343","author":"TM Chan","year":"2000","unstructured":"Chan TM, Li FK, Tang CS et al (2000) Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 343:1156\u20131162","journal-title":"N Engl J Med"},{"key":"6367_CR43","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1093\/rheumatology\/kep346","volume":"49","author":"D Isenberg","year":"2010","unstructured":"Isenberg D, Appel GB, Contreras G et al (2010) Influence of race\/ethnicity on response to lupus nephritis treatment: the ALMS study. Rheumatology 49:128\u2013140. https:\/\/doi.org\/10.1093\/rheumatology\/kep346","journal-title":"Rheumatology"},{"key":"6367_CR44","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1053\/j.ajkd.2012.11.042","volume":"61","author":"M Walsh","year":"2013","unstructured":"Walsh M, Solomons N, Lisk L et al (2013) Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis with poor kidney function: a subgroup analysis of the aspreva lupus management study. Am J Kidney Dis 61:710\u2013715. https:\/\/doi.org\/10.1053\/j.ajkd.2012.11.042","journal-title":"Am J Kidney Dis"},{"key":"6367_CR45","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1111\/j.1440-1797.2008.00975.x","volume":"13","author":"Z Tang","year":"2008","unstructured":"Tang Z, Yang G, Yu C et al (2008) Effects of mycophenolate mofetil for patients with crescentic lupus nephritis. Nephrology 13:702\u2013707. https:\/\/doi.org\/10.1111\/j.1440-1797.2008.00975.x","journal-title":"Nephrology"},{"key":"6367_CR46","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s12969-018-0279-0","volume":"16","author":"JC Cooper","year":"2018","unstructured":"Cooper JC, Rouster-Stevens K, Wright TB et al (2018) Pilot study comparing the childhood arthritis and rheumatology research alliance consensus treatment plans for induction therapy of juvenile proliferative lupus nephritis. Pediatr Rheumatol Online J 16:65. https:\/\/doi.org\/10.1186\/s12969-018-0279-0","journal-title":"Pediatr Rheumatol Online J"},{"key":"6367_CR47","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1177\/0961203319836712","volume":"28","author":"E Smith","year":"2019","unstructured":"Smith E, Al-Abadi E, Armon K et al (2019) Outcomes following mycophenolate mofetil versus cyclophosphamide induction treatment for proliferative juvenile-onset lupus nephritis. Lupus 28:613\u2013620. https:\/\/doi.org\/10.1177\/0961203319836712","journal-title":"Lupus"},{"key":"6367_CR48","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1007\/s00467-020-04501-x","volume":"35","author":"A Suhlrie","year":"2020","unstructured":"Suhlrie A, Hennies I, Gellermann J et al (2020) Twelve-month outcome in juvenile proliferative lupus nephritis: results of the German registry study. Pediatr Nephrol 35:1235\u20131246. https:\/\/doi.org\/10.1007\/s00467-020-04501-x","journal-title":"Pediatr Nephrol"},{"key":"6367_CR49","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1093\/ndt\/gfab152","volume":"37","author":"S Demir","year":"2021","unstructured":"Demir S, G\u00fclhan B, \u00d6zen S et al (2021) Long term renal survival of pediatric patients with lupus nephritis. Nephrol Dial Transplant 37:1069\u20131077. https:\/\/doi.org\/10.1093\/ndt\/gfab152","journal-title":"Nephrol Dial Transplant"},{"key":"6367_CR50","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1007\/s40620-022-01438-2","volume":"36","author":"M Chbihi","year":"2022","unstructured":"Chbihi M, Eveillard LA, Riller Q et al (2022) Induction therapy for pediatric onset class IV lupus nephritis: mycophenolate mofetil versus cyclophosphamide. J Nephrol 36:829\u2013839. https:\/\/doi.org\/10.1007\/s40620-022-01438-2","journal-title":"J Nephrol"},{"key":"6367_CR51","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1177\/0961203312458466","volume":"21","author":"R Sundel","year":"2012","unstructured":"Sundel R, Solomons N, Lisk L (2012) Efficacy of mycophenolate mofetil in adolescent patients with lupus nephritis: evidence from a two-phase, prospective randomized trial. Lupus 21:1433\u20131443. https:\/\/doi.org\/10.1177\/0961203312458466","journal-title":"Lupus"},{"key":"6367_CR52","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1016\/s0140-6736(21)00578-x","volume":"397","author":"BH Rovin","year":"2021","unstructured":"Rovin BH, Teng YKO, Ginzler EM et al (2021) Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 397:2070\u20132080. https:\/\/doi.org\/10.1016\/s0140-6736(21)00578-x","journal-title":"Lancet"},{"key":"6367_CR53","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","volume":"383","author":"R Furie","year":"2020","unstructured":"Furie R, Rovin BH, Houssiau F et al (2020) Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med 383:1117\u20131128. https:\/\/doi.org\/10.1056\/NEJMoa2001180","journal-title":"N Engl J Med"},{"key":"6367_CR54","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.kint.2021.08.027","volume":"101","author":"BH Rovin","year":"2022","unstructured":"Rovin BH, Furie R, Teng YKO et al (2022) A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis. Kidney Int 101:403\u2013413. https:\/\/doi.org\/10.1016\/j.kint.2021.08.027","journal-title":"Kidney Int"},{"key":"6367_CR55","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1136\/annrheumdis-2020-217101","volume":"79","author":"HI Brunner","year":"2020","unstructured":"Brunner HI, Abud-Mendoza C, Viola DO et al (2020) Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial. Ann Rheum Dis 79:1340\u20131348. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217101","journal-title":"Ann Rheum Dis"},{"key":"6367_CR56","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.2215\/cjn.01070118","volume":"13","author":"LM Gomez Mendez","year":"2018","unstructured":"Gomez Mendez LM, Cascino MD, Garg J et al (2018) Peripheral blood B cell depletion after rituximab and complete response in lupus nephritis. Clin J Am Soc Nephrol 13:1502\u20131509. https:\/\/doi.org\/10.2215\/cjn.01070118","journal-title":"Clin J Am Soc Nephrol"},{"key":"6367_CR57","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1136\/annrheumdis-2021-220920","volume":"81","author":"RA Furie","year":"2021","unstructured":"Furie RA, Aroca G, Cascino MD et al (2021) B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 81:100\u2013107. https:\/\/doi.org\/10.1136\/annrheumdis-2021-220920","journal-title":"Ann Rheum Dis"},{"key":"6367_CR58","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/art.41466","volume":"73","author":"Y Atisha-Fregoso","year":"2021","unstructured":"Atisha-Fregoso Y, Malkiel S, Harris KM et al (2021) CALIBRATE: a phase 2 randomized trial of rituximab plus cyclophosphamide followed by belimumab for the treatment of lupus nephritis. Arthritis Rheumatol 73:121\u2013131. https:\/\/doi.org\/10.1002\/art.41466","journal-title":"Arthritis Rheumatol"},{"key":"6367_CR59","doi-asserted-by":"publisher","first-page":"4001","DOI":"10.1007\/s00467-023-06025-6","volume":"38","author":"EY-H Chan","year":"2023","unstructured":"Chan EY-H, Wong S-W, Lai FF-Y et al (2023) Long-term outcomes with rituximab as add-on therapy in severe childhood-onset lupus nephritis. Pediatr Nephrol 38:4001\u20134011. https:\/\/doi.org\/10.1007\/s00467-023-06025-6","journal-title":"Pediatr Nephrol"},{"key":"6367_CR60","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/nrneph.2009.130","volume":"5","author":"BH Rovin","year":"2009","unstructured":"Rovin BH (2009) Lupus nephritis treatment: are we beyond cyclophosphamide? Nat Rev Nephrol 5:492\u2013494. https:\/\/doi.org\/10.1038\/nrneph.2009.130","journal-title":"Nat Rev Nephrol"},{"key":"6367_CR61","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1038\/ki.2012.203","volume":"82","author":"J Hogan","year":"2012","unstructured":"Hogan J, Schwenk M, Radhakrishnan J (2012) Should mycophenolate mofetil replace cyclophosphamide as first-line therapy for severe lupus nephritis? Kidney Int 82:1256\u20131260. https:\/\/doi.org\/10.1038\/ki.2012.203","journal-title":"Kidney Int"},{"key":"6367_CR62","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1093\/ndt\/gfw068","volume":"31","author":"CC Mok","year":"2016","unstructured":"Mok CC (2016) Con: Cyclophosphamide for the treatment of lupus nephritis. Nephrol Dial Transplant 31:1053\u20131057. https:\/\/doi.org\/10.1093\/ndt\/gfw068","journal-title":"Nephrol Dial Transplant"},{"key":"6367_CR63","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1002\/art.40930","volume":"71","author":"M Aringer","year":"2019","unstructured":"Aringer M, Costenbader K, Daikh D et al (2019) 2019 European League Against Rheumatism\/American College of Rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol 71:1400\u20131412. https:\/\/doi.org\/10.1002\/art.40930","journal-title":"Arthritis Rheumatol"},{"key":"6367_CR64","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.kint.2017.11.023","volume":"93","author":"IM Bajema","year":"2018","unstructured":"Bajema IM, Wilhelmus S, Alpers CE et al (2018) Revision of the International Society of Nephrology\/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices. Kidney Int 93:789\u2013796. https:\/\/doi.org\/10.1016\/j.kint.2017.11.023","journal-title":"Kidney Int"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-024-06367-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-024-06367-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-024-06367-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T11:26:36Z","timestamp":1726745196000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00467-024-06367-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,12]]},"references-count":64,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["6367"],"URL":"https:\/\/doi.org\/10.1007\/s00467-024-06367-9","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"type":"print","value":"0931-041X"},{"type":"electronic","value":"1432-198X"}],"subject":[],"published":{"date-parts":[[2024,4,12]]},"assertion":[{"value":"6 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SEW serves on the data monitoring committee overseeing AstraZeneca and Novartis-sponsored clinical trials. JCC, no conflicts to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}